Semaphorin3A increases M1-like microglia and retinal ganglion cell apoptosis after optic nerve injury.
Microglia polarization, M1/M2-like
Neuroinflammation
retinal ganglion cells (RGCs)
semaphorin3A (Sema3A)
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
18
02
2021
accepted:
04
05
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
The mechanisms leading to retinal ganglion cell (RGC) death after optic nerve injury have not been fully elucidated. Current evidence indicates that microglial activation and M1- and M2-like dynamics may be an important factor in RGC apoptosis after optic nerve crush (ONC). Semaphorin3A (Sema3A) is a classic axonal guidance protein,which has been found to have a role in neuroinflammation processes. In this study, we investigated the contribution of microglial-derived Sema3A to progressive RGC apoptosis through regulating paradigm of M1- and M2-like microglia after ONC. A mouse ONC model and a primary microglial-RGC co-culture system were used in the present study. The expression of M1- and M2-like microglial activation markers were assessed by real-time polymerase chain reaction (RT-qPCR). Histological and Western blot (WB) analyses were used to investigate the polarization patterns of microglia transitions and the levels of Sema3A. RGC apoptosis was investigated by TUNEL staining and caspase-3 detection. Levels of Sema3A in the mouse retina increased after ONC. Treatment of mice with the stimulating factor 1 receptor antagonist PLX3397 resulted in a decrease of retinal microglia. The levels of CD16/32 (M1) were up-regulated at days 3 and 7 post-ONC. However, CD206 (M2) declined on day 7 after ONC. Exposure to anti-Sema3A antibodies (anti-Sema3A) resulted in a decrease in the number of M1-like microglia, an increase in the number of M2-like microglia, and the amelioration of RGC apoptosis. An increase in microglia-derived Sema3A in the retina after ONC partially leads to a continuous increase of M1-like microglia and plays an important role in RGC apoptosis. Inhibition of Sema3A activity may be a novel approach to the prevention of RGC apoptosis after optic nerve injury.
Sections du résumé
BACKGROUND
BACKGROUND
The mechanisms leading to retinal ganglion cell (RGC) death after optic nerve injury have not been fully elucidated. Current evidence indicates that microglial activation and M1- and M2-like dynamics may be an important factor in RGC apoptosis after optic nerve crush (ONC). Semaphorin3A (Sema3A) is a classic axonal guidance protein,which has been found to have a role in neuroinflammation processes. In this study, we investigated the contribution of microglial-derived Sema3A to progressive RGC apoptosis through regulating paradigm of M1- and M2-like microglia after ONC.
METHOD
METHODS
A mouse ONC model and a primary microglial-RGC co-culture system were used in the present study. The expression of M1- and M2-like microglial activation markers were assessed by real-time polymerase chain reaction (RT-qPCR). Histological and Western blot (WB) analyses were used to investigate the polarization patterns of microglia transitions and the levels of Sema3A. RGC apoptosis was investigated by TUNEL staining and caspase-3 detection.
RESULTS
RESULTS
Levels of Sema3A in the mouse retina increased after ONC. Treatment of mice with the stimulating factor 1 receptor antagonist PLX3397 resulted in a decrease of retinal microglia. The levels of CD16/32 (M1) were up-regulated at days 3 and 7 post-ONC. However, CD206 (M2) declined on day 7 after ONC. Exposure to anti-Sema3A antibodies (anti-Sema3A) resulted in a decrease in the number of M1-like microglia, an increase in the number of M2-like microglia, and the amelioration of RGC apoptosis.
CONCLUSIONS
CONCLUSIONS
An increase in microglia-derived Sema3A in the retina after ONC partially leads to a continuous increase of M1-like microglia and plays an important role in RGC apoptosis. Inhibition of Sema3A activity may be a novel approach to the prevention of RGC apoptosis after optic nerve injury.
Identifiants
pubmed: 34039431
doi: 10.1186/s13578-021-00603-7
pii: 10.1186/s13578-021-00603-7
pmc: PMC8157735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Références
Development. 2016 Feb 15;143(4):589-94
pubmed: 26884395
Lupus. 2012 Oct;21(12):1266-70
pubmed: 22875653
Trends Mol Med. 2013 Mar;19(3):157-64
pubmed: 23419749
Neuron. 2014 Apr 16;82(2):380-97
pubmed: 24742461
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1530-6
pubmed: 27035626
J Neurosci. 2014 Jun 25;34(26):8904-17
pubmed: 24966389
J Clin Invest. 2014 Nov;124(11):4807-22
pubmed: 25271625
Mult Scler. 2015 Nov;21(13):1632-43
pubmed: 26432853
Nat Cell Biol. 2006 Jun;8(6):615-22
pubmed: 16715077
Neurochem Res. 2020 May;45(5):1072-1085
pubmed: 32052258
J Neuroinflammation. 2012 Feb 24;9:39
pubmed: 22361049
Glia. 2003 Dec;44(3):183-9
pubmed: 14603460
J Mol Med (Berl). 2018 Jul;96(7):713-724
pubmed: 29909462
Neuroscience. 2009 Feb 6;158(3):995-1006
pubmed: 18675321
Nature. 2014 May 8;509(7499):189-94
pubmed: 24776795
Sci Transl Med. 2015 Oct 14;7(309):309ra165
pubmed: 26468327
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
Inflammopharmacology. 2018 Jun;26(3):655-665
pubmed: 29696565
Neurobiol Aging. 2013 Apr;34(4):1051-9
pubmed: 23062700
J Immunol. 2018 Aug 1;201(3):897-907
pubmed: 29898965
J Neuroinflammation. 2014 Jul 25;11:127
pubmed: 25062954
J Neurosci. 1986 Aug;6(8):2163-78
pubmed: 3018187
Front Aging Neurosci. 2017 Jul 06;9:214
pubmed: 28729832
Brain Res. 2020 Jan 15;1727:146555
pubmed: 31733191
Neuron. 2011 Aug 11;71(3):433-46
pubmed: 21835341
Nat Neurosci. 2018 Mar;21(3):329-340
pubmed: 29463850
Int Immunol. 2015 Sep;27(9):459-66
pubmed: 25855660
Glia. 2006 Nov 1;54(6):545-56
pubmed: 16906543
J Neurotrauma. 2016 Oct 1;33(19):1732-1750
pubmed: 26486881
Mol Vis. 2019 Nov 14;25:722-730
pubmed: 31814697
Blood. 2006 Apr 15;107(8):3321-9
pubmed: 16380453
Invest Ophthalmol Vis Sci. 2012 Dec 19;53(13):8367-77
pubmed: 23139269
Prog Retin Eye Res. 2018 Jan;62:58-76
pubmed: 29081352
Brain Res. 2015 Jun 22;1611:65-73
pubmed: 25791621
Mol Neurobiol. 2017 Aug;54(6):4094-4112
pubmed: 27318678
Neuron. 2014 Sep 3;83(5):1098-116
pubmed: 25132469
Exp Eye Res. 2013 Feb;107:52-8
pubmed: 23206928
Acta Neuropathol Commun. 2018 Jul 23;6(1):66
pubmed: 30037353
Annu Rev Immunol. 2017 Apr 26;35:441-468
pubmed: 28226226
J Neurosci. 2006 Feb 8;26(6):1730-8
pubmed: 16467521
Annu Rev Vis Sci. 2018 Sep 15;4:45-77
pubmed: 29852094
Neurotherapeutics. 2018 Jul;15(3):541-553
pubmed: 29717413
Prog Retin Eye Res. 2017 Mar;57:1-25
pubmed: 28064040
Mol Neurodegener. 2018 Mar 1;13(1):11
pubmed: 29490706
J Neurosci. 2015 Jul 8;35(27):9977-89
pubmed: 26156998
J Exp Med. 2010 Dec 20;207(13):2943-57
pubmed: 21098092
Brain Res. 2012 Dec 13;1489:90-7
pubmed: 23103505
J Biol Chem. 2003 Oct 31;278(44):42985-91
pubmed: 12933805
Front Cell Neurosci. 2018 Jun 13;12:160
pubmed: 29950973
J Biol Chem. 2002 Dec 20;277(51):49799-807
pubmed: 12376549
Front Immunol. 2019 Mar 22;10:550
pubmed: 30967873
Nat Immunol. 2010 Jul;11(7):594-600
pubmed: 20512151
Cell Mol Life Sci. 2009 Feb;66(4):649-66
pubmed: 18953684
Front Cell Dev Biol. 2019 Oct 15;7:225
pubmed: 31681759
Prog Neurobiol. 2019 Feb;173:18-40
pubmed: 29864456